Core Viewpoint - The market sentiment is cautious, with the Kexin Pharmaceutical ETF (588130) experiencing a decline of approximately 1% despite a strong performance from some constituent stocks like Sanofi, which saw its share price increase by over 10% due to significant earnings forecasts [1] Group 1: Company Performance - Sanofi has forecasted a revenue of around 4.2 billion yuan and a net profit of approximately 2.9 billion yuan for 2025, representing year-on-year increases of 251.76% and 311.35% respectively, primarily driven by the confirmation of a 2.89 billion yuan upfront payment from the Pfizer 707 project [1] - The performance of constituent stocks within the ETF is notably divergent, with Sanofi leading the gains in the sector [1] Group 2: Industry Trends - Huafu Securities believes that a new cycle of global innovative drugs has begun, with China poised to fully participate and potentially lead this trend [1] - Guosen Securities emphasizes the importance of focusing on new technological directions, particularly in areas such as dual antibodies, small nucleic acids, AI healthcare, and brain-computer interfaces [1] Group 3: Market Concerns - Recent reports of Nipah virus infections in West Bengal, India, with five confirmed cases and around 100 close contacts under home quarantine, have raised concerns in the capital markets regarding overseas epidemic dynamics [1]

中共中央政治局常委、国务院总理李强1月19日下午主持召开专家、企业家和教科文卫体等领域代表座 谈会，听取对《政府工作报告》和《"十五五"规划纲要（草案）》两个征求意见稿的意见建议。2025 年，中国国内生产总值（GDP）1401879亿元，首次跃上140万亿元新台阶，按不变价格计算，比上年增 长5.0%。2025年社会消费品零售总额突破50万亿元，超大规模市场优势持续显现。 近期海外焦点落在美国对格陵兰权益争夺的升级上，虽然TACO再现，但从去年开始的一系列事件，已 在一定程度上传导到全球货币体系和信用体系上，受益的品种已经演绎多时，而今年最大的黑天鹅也可 能来源于此。 经济数据层面，近期美国商务部和劳工统计局发布多个宏观经济数据。美国2025年第三季度核心PCE指 数年化终值环比升2.9%，预期升2.9%，初值升2.9%；PCE物价指数年化终值环比升2.8%，预期升 3.5%，初值升2.8%；就业方面，美国上周初请失业金人数为20万人，预期21万人，前值自19.8万人修正 至19.9万人。宏观方面，美国2025年第三季度实际GDP年化季率终值升4.4%，预期升4.3%，初值升 4.3%。美国经济软着陆预期仍 ...

Core Viewpoint - By 2025, China's innovative pharmaceuticals are expected to demonstrate significant global competitiveness, with record overseas transactions and many companies turning profitable [1][2]. Domestic Review - The global competitiveness of Chinese innovative drugs is highlighted, with a record-breaking overseas transaction total exceeding $135 billion in 2025, and upfront payments reaching $7 billion. The average deal size has increased from $600 million to $900 million [2]. - A comprehensive support system from policy, including review and approval processes to medical insurance payments, is being established, leading to a rapid increase in market share for innovative drugs, particularly in oncology and immunology, which now exceeds 32% [2]. - Companies like BeiGene and Innovent Biologics have already turned profitable, with others like CanSino Biologics and Zai Lab expected to follow suit in the next three years, indicating a positive cycle of capital influx, R&D iteration, and value realization [2]. Overseas Review - The S&P Biotechnology Index has risen over 50% from its bottom in the second half of 2025, driven by interest rate cuts that have shifted funds from tech stocks to biotech [3]. - Major pharmaceutical companies (MNCs) are actively pursuing mergers and acquisitions to supplement their pipelines, particularly in oncology and immunology, as they face a "patent cliff" with key drugs like Keytruda and Opdivo losing patent protection by 2027-2028 [3]. Assessment - Chinese companies are becoming significant partners for the top 20 MNCs, with Chinese transaction amounts accounting for 40% of the global innovative drug market. China is transitioning from a "fast-follower" to a "smart-innovator" in fields like PD-1 bispecific antibodies, ADCs, and small nucleic acids, leading in pipeline numbers and clinical progress [4]. - The speed and cost advantages of Chinese innovative drug companies are notable, with patient recruitment occurring at 2-5 times the speed of international counterparts and costs being half that of Western companies [4]. Key Tracks and Investment Opportunities - Bispecific antibodies are expected to surpass $120 billion in global sales, with Chinese companies leading the development of second-generation IO products [5]. - ADCs are seeing significant contributions from China, with over half of the global pipeline, and are expected to achieve proof of concept (POC) validation by 2026 [5]. - Combination therapies in oncology are showing synergistic effects, with key clinical data expected in 2026 [5]. - The market for iRAS inhibitors is projected to exceed $8 billion in the U.S., with critical breakthroughs anticipated in 2026 [5]. - Small nucleic acids are expanding into broader applications, with key products expected to commercialize and deliver critical data in 2026 [5]. - Protein degradation technologies are advancing rapidly, with numerous autoimmune disease targets expected to yield data in 2026 [5]. - The metabolic and cardiovascular fields are also poised for breakthroughs, with new targets addressing issues like muscle loss associated with GLP-1 therapies [5]. Main Lines and Recommended Focus - Recommended companies in the bispecific antibody space include CanSino Biologics, Innovent Biologics, and others [7]. - ADC-focused companies include I-Mab, Kelun-Biotech, and others [7]. - Small nucleic acid companies to watch include Ribobio, BIBO, and others [7]. - Strategic combinations to consider include CanSino Biologics, BeiGene, and others [8]. - Flexible combinations include BIBO, Eifang Biologics, and others [8]. - Stable combinations include Hengrui Medicine, China National Pharmaceutical Group, and others [8].

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

Group 1 - The core viewpoint of the article is that Sichuan Shuangma is actively involved in the biopharmaceutical sector, focusing on the incubation of innovative drugs through direct investment and incubator platforms [2] - The company has concentrated its efforts on several disease areas, including oncology, autoimmune diseases, metabolic disorders, and neurological diseases, and is developing a number of early-stage innovative drug enterprises with internationally competitive product data [2] - Sichuan Shuangma employs a systematic and platform-based incubation model to promote the transformation of research results into marketable products [2]

◎记者 赵明超 2025年春，创新药板块"忽如一夜春风来"，各家药企BD交易"千树万树梨花开"，一场轰轰烈烈的创新 药行情随之展开，在三季度上演"秋收"行情，但随后又迎来震荡调整，处于"冬藏"状态。 走过2025年的"秋收冬藏"行情之后，2026年的创新药行情如何演绎？整个医药板块有哪些投资机会？上 海证券报记者邀请平安医药精选股票基金经理周思聪、长城医药产业基金经理梁福睿、融通健康产业基 金经理万民远，就上述问题分享看法。 未来向好 创新药重估进行时 上海证券报：站在当前时点，如何看创新药行业2026年的投资机会？ 周思聪：2025年，创新药全球BD交易爆发式增长，验证了中国国内研发的质量，市场对创新药企业进 行重估，创新药板块强劲反弹，但目前基本还没有演绎创新药行业的业绩主线。 2026年，市场叙事将从广泛的估值重估转向基本面落地，市场将更加严苛地审视公司的每一个临床数 据、每一份销售财报和每一次BD交易的质量。能否持续产出有价值的创新成果，以及能否将这些成果 高效地转化为商业收入，是决定未来公司价值的核心。未来的赢家将是那些能够将其科学创新成功地转 化为商业成果的公司。 梁福睿：2025年二、三季度创新 ...

Core Insights - The report emphasizes the importance of innovation in the pharmaceutical and biotechnology industry, particularly focusing on the overseas expansion of innovative drugs and the adoption of new technologies [1][4]. - The investment rating for the sector is maintained at "outperform the market" [2]. Group 1: Market Overview and Trends - The overseas market for innovative drugs and the CXO industry is expected to perform exceptionally well in 2025, driven by continuous business development (BD) activities, strong clinical data, and supportive policies [4]. - The domestic supply and demand remain stable, with a shift in payment systems favoring innovation. National health expenditure increased by 4.7% year-on-year in the first 11 months of 2025, marking a recovery after two years of decline [4]. - The report highlights the significant growth potential in new drug forms such as dual antibodies and small nucleic acid drugs, as well as innovations in AI healthcare and brain-machine interfaces [4]. Group 2: Investment Recommendations - The report recommends focusing on companies with global competitiveness and differentiated innovation capabilities, as well as domestic CXO leaders with high barriers in cost control, technology accumulation, and production capacity [4]. - Recommended stocks include Mindray Medical, WuXi AppTec, Kelaiying, Aier Eye Hospital, and several others, with specific mention of H-shares like Kelun-Bio and CanSino Biologics [4][5]. Group 3: Financial Performance and Projections - The report provides a detailed strategy portfolio for 2026, listing companies along with their projected net profits and price-to-earnings (PE) ratios, indicating a generally positive outlook for the sector [5]. - The pharmaceutical sector's overall performance in 2025 was strong, with significant gains in sub-sectors such as medical services and chemical pharmaceuticals, driven by BD collaborations and clinical data releases [12][23]. Group 4: Fund Holdings and Market Sentiment - As of Q4 2025, the net asset value of pharmaceutical funds decreased by 9.0%, with a notable shift where passive funds surpassed active funds for the first time since 2019 [25][32]. - The report indicates a decline in the proportion of pharmaceutical holdings in both active and non-pharmaceutical funds, with a concentration in chemical preparations and other biological products [32][40].

Group 1 - The core viewpoint of the article highlights that the technology sector is a key theme in the market's "new and old coexistence" structure leading up to 2026, with a focus on the principle of "AI technology moving downstream" [1] - The market structure is shifting from the first wave characterized by "eight immortals crossing the sea" to a second wave represented by the "four great kings," where technology plays a significant role [1] - Within the technology sector, funds are expanding their focus from core industries with strong fundamentals to downstream sectors such as commercial aerospace and AI applications [1] Group 2 - The Hong Kong Stock Connect Technology Index (931573) tracked by the Hong Kong Technology ETF (513020) has outperformed the Hang Seng Technology Index in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors [2] - From the base date at the end of 2014 to the end of 2025, the cumulative return of the Hong Kong Stock Connect Technology Index is 224.25%, significantly exceeding the 83.87% return of the Hang Seng Technology Index by over 140% [2] - The Hong Kong Stock Connect Technology Index has consistently outperformed similar indices, including the Hang Seng Internet Technology Index and the Hang Seng Healthcare Index [2]

Core Insights - The Chinese healthcare industry experienced a significant surge in 2025, marked by a record number of innovative medical devices and drugs approved for market entry, indicating a growing focus on innovation in the sector [1][3] - The total value of overseas business development (BD) transactions for innovative drugs reached $135.7 billion in 2025, accounting for 49% of the global total, surpassing the United States for the first time [3] - The IPO market for healthcare companies in China saw a revival, with 37 companies successfully listed in 2025, doubling the number from 2024, reflecting strong investor interest in the sector [7] Innovation in Medical Devices and Drugs - In 2025, 109 innovative medical devices were approved, with a 19.67% year-on-year increase in Class III devices, while 76 innovative drugs were approved, focusing on advanced fields like oncology and autoimmune diseases [1] - The rapid growth in innovative drug approvals and medical device registrations highlights China's increasing capabilities in healthcare innovation [1][8] Business Development and Market Dynamics - The number of overseas BD transactions for innovative drugs reached 157 in 2025, with a total transaction value of $135.7 billion, both figures representing historical highs [3] - The increasing recognition of Chinese innovative drugs by global pharmaceutical companies is evident, particularly as they face pressures from patent expirations and global competition [8] IPO Activity and Market Sentiment - The healthcare sector in China saw a resurgence in IPO activity, with 37 companies going public in 2025, compared to 17 in 2024, indicating a robust market sentiment [7] - Over 60 healthcare companies are currently in the IPO pipeline on the Hong Kong Stock Exchange, reflecting sustained investor enthusiasm for the healthcare sector [7] Challenges and Industry Landscape - Despite the growth, challenges persist, including difficulties in financing and market entry for medical companies, exacerbated by domestic healthcare cost controls and intensified competition [7] - The industry is undergoing significant consolidation, presenting both opportunities and challenges for companies navigating this complex landscape [7][11] AI Integration in Healthcare - AI technology is increasingly integrated into the healthcare sector, enhancing the efficiency and safety of medical devices and drug development processes [10] - The shift towards data-driven, proactive healthcare solutions is transforming traditional practices, with AI expected to play a crucial role in future clinical pathways [10] Investment Trends and Future Outlook - The investment landscape in the healthcare sector is shifting towards high-tech, innovative companies, with a notable decrease in the number of financing events but an increase in total investment amounts [16] - The next 5-10 years are anticipated to be a golden period for innovation in Chinese healthcare, with a focus on projects that address unmet clinical needs [17]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Views - The report highlights the ongoing decline in the national population and birth rates, with a significant increase in the elderly population, which is expected to drive demand for home medical devices and supplies [5][21] - The report emphasizes the long-term positive trend in the innovative drug sector, supported by the strength of China's innovative drug companies in global competition [7] - The medical device sector is showing signs of improvement, with major companies reporting better performance in Q3, indicating a potential recovery in the industry [9] Summary by Relevant Sections Industry Overview - As of January 26, 2026, the closing index stands at 8623.36, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of January 19-23, 2026, the A-share pharmaceutical sector fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 0.05 percentage points [6][24] - The medical device sector is expected to attract more investment as the pressure from centralized procurement diminishes [9][30] Population and Demographics - By the end of 2025, the total population of China was 1,404.89 million, with a natural population growth rate of -2.41% [15] - The elderly population (aged 65 and above) reached 22,365 million, accounting for 15.9% of the total population, indicating a trend towards an aging society [18][20] Investment Recommendations - The report suggests focusing on companies in the elderly care medical sector, such as Yuyue Medical, Kefu Medical, and Loxin Medical, due to the anticipated increase in demand for home medical devices [5][22] - In the innovative drug sector, companies like Innovent Biologics and Kintor Pharmaceutical are highlighted as beneficiaries of the growing global participation of Chinese innovative drug firms [7][27] - For the medical device sector, companies such as Mindray and Hunan Aohua are recommended due to their improving performance and market position [9][30] Future Outlook - The report anticipates a recovery in the medical device sector as procurement policies become more reasonable and the pressure from centralized procurement decreases [30] - The innovative drug sector is expected to continue its upward trajectory, with more innovative projects anticipated in 2026 [26][28]